AR003418A1 - Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación. - Google Patents

Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.

Info

Publication number
AR003418A1
AR003418A1 ARP960102465A AR10246596A AR003418A1 AR 003418 A1 AR003418 A1 AR 003418A1 AR P960102465 A ARP960102465 A AR P960102465A AR 10246596 A AR10246596 A AR 10246596A AR 003418 A1 AR003418 A1 AR 003418A1
Authority
AR
Argentina
Prior art keywords
nipecotic
preparation
pharmaceutical composition
enil
methylene
Prior art date
Application number
ARP960102465A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR003418A1 publication Critical patent/AR003418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una nueva composición farmacéutica caracterizada porque comprende (a) R(-)-N-(4,4-di(3-metiltien-2-il)but-3-enil)-nipecótico o una sal farmacéuticamente aceptable de la misma, (b) uno o más antioxidantesf armacéuticamente aceptables en una cantidad suficiente paraestabilizar R(-)-N-(4,4-di(3-metiltien-2-il)but-3-enil)-nipecótico o su sal farmacéuticamente aceptable y (c) opcionalmente un vehículo farmacéuticamenteaceptable y un procedimientopara la preparación de dicha composición.
ARP960102465A 1995-05-05 1996-05-06 Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación. AR003418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK52395 1995-05-05

Publications (1)

Publication Number Publication Date
AR003418A1 true AR003418A1 (es) 1998-08-05

Family

ID=8094516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102465A AR003418A1 (es) 1995-05-05 1996-05-06 Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.

Country Status (26)

Country Link
US (1) US5866590A (es)
EP (1) EP0830132B1 (es)
JP (1) JP3195360B2 (es)
KR (1) KR100440354B1 (es)
CN (1) CN1092959C (es)
AR (1) AR003418A1 (es)
AT (1) ATE211911T1 (es)
AU (1) AU707508B2 (es)
BR (1) BR9608120A (es)
CA (1) CA2220019C (es)
CZ (1) CZ292256B6 (es)
DE (1) DE69618586T2 (es)
DK (1) DK0830132T3 (es)
EG (1) EG23781A (es)
ES (1) ES2171669T3 (es)
HU (1) HU223075B1 (es)
IL (1) IL118142A (es)
MX (1) MX9708394A (es)
MY (1) MY115016A (es)
NO (1) NO318599B1 (es)
NZ (1) NZ307159A (es)
PL (1) PL183678B1 (es)
PT (1) PT830132E (es)
UA (1) UA43402C2 (es)
WO (1) WO1996034606A1 (es)
ZA (1) ZA963478B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
WO1999006045A1 (en) * 1997-08-01 1999-02-11 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999017771A1 (en) * 1997-10-02 1999-04-15 H. Lundbeck A/S Granular preparations of 5-(2-ethyl- 2h-tetrazol- 5-yl)-1-methyl-1, 2,3,6-tetrahydropyridine
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
EP1303273A1 (en) * 2000-05-26 2003-04-23 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
AU2000249111A1 (en) * 2000-05-30 2001-12-11 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
AU2013257707A1 (en) * 2012-05-08 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US501090A (en) * 1893-07-11 gennert
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies

Also Published As

Publication number Publication date
CZ292256B6 (cs) 2003-08-13
ES2171669T3 (es) 2002-09-16
ZA963478B (en) 1996-11-13
CZ338897A3 (cs) 1998-03-18
EP0830132A1 (en) 1998-03-25
JPH10505359A (ja) 1998-05-26
MY115016A (en) 2003-03-31
KR100440354B1 (ko) 2004-09-18
NO318599B1 (no) 2005-04-18
DE69618586T2 (de) 2002-09-05
CN1092959C (zh) 2002-10-23
NO975076D0 (no) 1997-11-04
HUP9802741A3 (en) 1999-04-28
ATE211911T1 (de) 2002-02-15
CA2220019A1 (en) 1996-11-07
NZ307159A (en) 1998-10-28
PL183678B1 (pl) 2002-06-28
CA2220019C (en) 2007-12-11
IL118142A0 (en) 1996-09-12
JP3195360B2 (ja) 2001-08-06
AU5644196A (en) 1996-11-21
AU707508B2 (en) 1999-07-15
DK0830132T3 (da) 2002-04-29
DE69618586D1 (de) 2002-02-21
HUP9802741A2 (hu) 1999-03-29
CN1183721A (zh) 1998-06-03
BR9608120A (pt) 1999-02-09
HU223075B1 (hu) 2004-03-01
US5866590A (en) 1999-02-02
PT830132E (pt) 2002-07-31
IL118142A (en) 1999-11-30
NO975076L (no) 1997-11-04
PL323138A1 (en) 1998-03-16
MX9708394A (es) 1998-02-28
WO1996034606A1 (en) 1996-11-07
EP0830132B1 (en) 2002-01-16
UA43402C2 (uk) 2001-12-17
EG23781A (en) 2007-08-13

Similar Documents

Publication Publication Date Title
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
AR003418A1 (es) Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.
ES2123910T3 (es) Composiciones que contienen sales anfoteras de alfa-hidroxiacidos y monocaprilato de glicerol.
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
DE69233671D1 (de) Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV
MX9206851A (es) Sales organicas de n,n'-diacetil cistina, proceso para su preparacion y composicion farmaceutica que las contiene.
ES2097546T3 (es) Preparaciones cosmeticas desodorantes que contienen esteres di- o trigliceridos.
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
UY24436A1 (es) Formulaciones orales de paroxetina de liberación controlada y retardada
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
ES2148593T3 (es) Compuestos retinoides trienoicos novedosos y metodos.
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
MX9204342A (es) Indoles.
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
MX171542B (es) Composiciones farmaceuticas que contienen deoxirribonucleosidos para cicatrizacion de heridas
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
AR013559A1 (es) USO DE DERIVADOS DE PIRROLIDINA PARA LA PREPARACIoN DE MEDICAMENNTOS DESTINADOS AL TRATAMIENTO DEL ABUSO DE DROGAS O DE SUSTANCIAS QUE DAN ORIGEN A LA ADICCIoN O AL USO EXCESIVO DE DROGAS , CON EXCEPCIoN DEL ABUSO DEL ALCOHOL, MEDIANTE LA REDUCCIoN DE LA AUTO-MEDICACIoN DE DICHAS DROGAS POR PARTE DE
AR008236A1 (es) Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica
NO923266L (no) Heksahydrobenzo(f)quinolinoner

Legal Events

Date Code Title Description
FG Grant, registration